Share on StockTwits

Gevo (NASDAQ:GEVO) CFO Mike Willis sold 18,167 shares of Gevo stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $0.94, for a total transaction of $17,076.98. Following the transaction, the chief financial officer now directly owns 122,374 shares in the company, valued at approximately $115,032. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of research firms have recently commented on GEVO. Analysts at Cowen and Company cut their price target on shares of Gevo to $1.00 in a research note on Friday, May 16th. Separately, analysts at Zacks downgraded shares of Gevo from an “outperform” rating to a “neutral” rating in a research note on Thursday, May 8th. They now have a $1.30 price target on the stock. Finally, analysts at Zacks upgraded shares of Gevo from a “neutral” rating to an “outperform” rating in a research note on Wednesday, April 9th. They now have a $1.50 price target on the stock.

Gevo (NASDAQ:GEVO) traded down 0.93% on Thursday, hitting $0.9114. 173,630 shares of the company’s stock traded hands. Gevo has a 52-week low of $0.73 and a 52-week high of $2.30. The stock has a 50-day moving average of $0.94 and a 200-day moving average of $1.20. The company’s market cap is $61.8 million.

Gevo (NASDAQ:GEVO) last announced its earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.03. The company had revenue of $0.90 million for the quarter, compared to the consensus estimate of $1.70 million. During the same quarter last year, the company posted ($0.45) earnings per share. Gevo’s revenue was down 74.3% compared to the same quarter last year. Analysts expect that Gevo will post $-0.67 EPS for the current fiscal year.

Gevo, Inc, is a renewable chemicals and advanced biofuels company. The Company is focused on the development and commercialization of alternatives to petroleum-based products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.